Seer reported revenue of $3.3 million for the first quarter of 2022, a significant increase compared to $62 thousand in the same period last year. The company's net loss was $23.6 million, and it continues to expect full-year 2022 revenue to be in the range of $14.0 million to $16.0 million.
Revenue for Q1 2022 was $3.3 million.
Delivered first Proteograph Product Suite orders across multiple geographies as part of Broad Commercial release.
Published a study in PNAS demonstrating performance of the Proteograph Product Suite.
Scott Thomas was hired as Chief Commercial Officer.
Seer continues to expect full year 2022 revenue to be in the range of $14.0 million to $16.0 million, and also expects to continue to increase investments in its commercial, operations, research and development activities to drive long-term growth and value creation.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance